Skip to content
Baret News – Lifestyle
Author:
Innovent Biologics
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
October 26, 2026
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
October 25, 2026
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
October 25, 2026
/DISREGARD RELEASE: Innovent Biologics/
October 23, 2026
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
October 23, 2026
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
October 13, 2026
2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
September 29, 2026
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
September 28, 2026
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
September 27, 2026
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
September 23, 2026
1
2
3
Next Page
→